Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

Spanish CDMO Laboratorios Farmacéuticos Rovi, known simply as Rovi, is part of a parade of biopharma contractors struggling to keep their manufacturing businesses growing in a post-COVID world. | ...

Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...